The Role of GLP-1 Analogues in Asthma Management

GLP-1 receptor agonists — best known as treatments for type 2 diabetes and obesity — are emerging as surprisingly powerful tools against asthma, particularly in patients where excess weight drives chronic airway inflammation that standard therapies struggle to control.

1. What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally released by the gut in response to food intake. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. GLP-1 receptor agonists (GLP-1 RAs) mimic this hormone pharmacologically, offering robust glucose control and — for many patients — significant weight loss.

Medications in this class include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and the newer dual-agonist tirzepatide (Mounjaro, Zepbound). They are currently approved for type 2 diabetes and/or obesity management.

Key Insight GLP-1 receptors are not limited to the pancreas. They are expressed throughout the body — including on lung epithelial cells, airway smooth muscle, and pulmonary immune cells — which explains why these drugs may have profound effects on respiratory health beyond glucose regulation.

2. The Obesity–Asthma Connection

Obesity and asthma are deeply intertwined. Adipose tissue, particularly visceral fat, is metabolically active — it releases pro-inflammatory cytokines (adipokines) that sustain systemic inflammation, alter airway mechanics through mechanical compression of the thorax, and reduce the response to standard inhaled corticosteroid therapy.

Patients with obesity-related asthma tend to have a distinct phenotype: neutrophilic rather than eosinophilic inflammation (non-Th2), poor response to biologics targeting the Th2 pathway, more frequent exacerbations, and greater emergency department utilization. This phenotype is precisely where GLP-1 receptor agonists appear most promising.

Key Pathophysiological Mechanisms:

• Systemic inflammation: Adipokines from excess fat tissue elevate circulating TNF-α, IL-6, and CRP, priming the airways for hyper-responsiveness.
• Steroid resistance: Obesity-related metabolic dysfunction reduces corticosteroid receptor sensitivity, making standard asthma therapy less effective.
• Mechanical restriction: Abdominal adiposity reduces functional residual capacity and tidal volume, worsening airflow obstruction.
• Insulin resistance: Emerging evidence links insulin resistance directly to asthma onset and poor control, independent of BMI.

3. How GLP-1 RAs Act on the Airways

The respiratory benefits of GLP-1 receptor agonists arise from multiple complementary mechanisms — both direct anti-inflammatory actions on lung tissue and indirect effects mediated by weight loss and metabolic improvement.

Direct Anti-Inflammatory Action

GLP-1 receptors are expressed on lung epithelial and endothelial cells. When GLP-1 RAs bind to these receptors, they suppress key inflammatory pathways involving eosinophils, neutrophils, and cytokines such as IL-5 and IL-13. This reduces airway hyper-responsiveness in both Th2 (allergic) and non-Th2 (metabolic/neutrophilic) asthma phenotypes.

Biomarker Evidence Clinical studies have found that liraglutide and semaglutide significantly reduce serum periostin — a validated biomarker of airway inflammation and remodeling — in adult asthma patients compared to other diabetes medications. This provides objective evidence of direct airway benefit beyond weight reduction alone.

Neuroinflammatory Pathway Modulation

A growing body of research suggests a link between asthma pathobiology and neuroinflammation. GLP-1 receptors are also found in the hindbrain, and GLP-1 signaling via the gut-brain axis may regulate neuroinflammatory pathways that contribute to airway hyper-responsiveness.

Indirect Benefits via Weight Loss and Metabolic Health

Weight reduction relieves mechanical pressure on the thorax, decreases circulating inflammatory mediators from adipose tissue, and restores corticosteroid sensitivity. Improved insulin sensitivity further dampens the metabolic-inflammatory cascade that drives obesity-associated asthma.

Expert Commentary (Current Opinion in Pulmonary Medicine, 2025) “Asthmatic patients living with obesity are more likely to experience poor disease control, higher exacerbation rates and poor response to conventional asthma therapies. Recent studies demonstrate that modulating insulin resistance may lead to improvement of asthma control, independent of weight.”

4. Clinical Evidence: What the Studies Show

The clinical data on GLP-1 RAs in asthma has accelerated rapidly in 2024–2025, transitioning from mechanistic hypotheses to large real-world outcome studies.

Landmark Study: Adolescents with Obesity and Asthma (JAMA Network Open, 2025)

A retrospective cohort study using the TriNetX global health research network identified 1,070 adolescents (average age 15.8 years) who were overweight or obese and had asthma. The GLP-1 RA group showed striking reductions across all asthma outcomes:

• 49% fewer asthma exacerbations
• 58% fewer asthma-related emergency department visits
• 34% lower risk of requiring systemic corticosteroids
• 28% lower risk of needing short-acting β-2 agonists

Real-World Adult Data (CHEST, 2025)

A large retrospective analysis using the TriNetX US Collaborative Network enrolled 1,066 propensity-matched obese adults with asthma per group. Compared to standard inhaled therapy alone, patients on GLP-1 RAs had significantly lower asthma exacerbation incidence (4.4% vs. 9.6%), representing a 5.2 percentage point absolute risk reduction, along with fewer prednisone prescriptions and better event-free survival over five years.

Meta-Analysis of 39 Randomized Controlled Trials

A comprehensive meta-analysis pooling data from 85,755 participants across 39 RCTs found a trend toward reduced asthma risk with GLP-1 RA use (RR 0.91). Separately, a meta-analysis of 28 RCTs with 77,485 participants found a 14% reduction in overall respiratory disease risk (RR 0.86, 95% CI 0.81–0.93, p < 0.0001).

Summary of Key Clinical Evidence:

Study / Source	Population	Key Finding	Signal
JAMA Netw Open, 2025 Huang et al. (TriNetX)	535 obese adolescents with asthma	49% fewer exacerbations; 58% fewer ER visits	Favorable
CHEST, 2025 TriNetX US Adults	1,066 obese adults with asthma	Exacerbations: 4.4% (GLP-1) vs 9.6% (control)	Favorable
BES Journal Meta-analysis, 2024 39 RCTs, 85,755 participants	T2DM or obesity patients	Trend toward reduced asthma risk (RR 0.91)	Modest/Trending
MDPI Comprehensive Review, 2025 28 RCTs, 77,485 participants	Mixed populations	14% lower respiratory disease risk	Favorable
CHEST 2025 Bayesian NMA Kulsum et al.	RCT data across GLP-1 classes	Semaglutide: decreased risk Tirzepatide: increased risk	Agent-Dependent

5. Not All GLP-1 Drugs Are Equal in Asthma

A critical finding from the 2025 CHEST conference Bayesian network meta-analysis is that the respiratory effects of GLP-1 receptor agonists vary significantly by agent — making drug selection an important clinical consideration for patients with comorbid asthma.

 

Drug	Brand Names	Notes	Asthma Signal
Semaglutide Ozempic · Wegovy · Rybelsus	Ozempic · Wegovy · Rybelsus	Most widely used. Associated with decreased asthma risk in multiple studies. Preferred agent for patients with comorbid asthma.	↓ Asthma risk
Liraglutide Victoza · Saxenda	Victoza · Saxenda	Reduces serum periostin (airway inflammation biomarker). Positive signal in obesity-related asthma.	↓ Inflammation marker
Tirzepatide Mounjaro · Zepbound	Mounjaro · Zepbound	Dual GIP/GLP-1 agonist. Associated with increased asthma risk per CHEST 2025 meta-analysis. Use with caution.	↑ Asthma risk (possible)
Dulaglutide / Exenatide Trulicity · Byetta	Trulicity · Byetta	No significant effect on asthma risk in most analyses. May offer indirect benefits through weight loss.	Neutral signal

 

Clinical Warning Clinicians prescribing tirzepatide to patients with asthma should exercise caution. The 2025 Bayesian NMA presented at CHEST 2025 found tirzepatide and albiglutide were associated with increased asthma risk. For patients with both type 2 diabetes or obesity and active asthma, semaglutide-based regimens appear to be the more favorable choice pending further RCT data.

6. Clinical Implications and Future Directions

Who May Benefit Most?

Current evidence points most strongly to patients with:

• Obesity-related asthma (BMI ≥30), particularly non-Th2 or steroid-refractory phenotypes
• Comorbid type 2 diabetes or metabolic syndrome requiring pharmacotherapy
• Frequent asthma exacerbations or high oral corticosteroid burden
• Poor response to standard inhaled corticosteroid regimens

Reducing the Steroid Burden

One of the most clinically significant potential benefits is reducing long-term corticosteroid exposure. Chronic systemic steroid use carries substantial morbidity — osteoporosis, adrenal suppression, hyperglycemia, and immune suppression. If GLP-1 RAs can reduce prednisone use in patients with difficult-to-control asthma, the downstream health benefits are substantial.

The GATA-3 Trial: A Pivotal Study in Progress

The GLP-1R Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) study is currently underway to rigorously determine whether GLP-1R signaling influences airway inflammation in obese asthmatics. This represents the first randomized controlled trial specifically designed to test GLP-1 RAs as asthma therapy, and its results will be pivotal for future treatment guidelines.

The Road Ahead GLP-1 receptor agonists represent a genuine convergence point between endocrinology and pulmonology. As the GATA-3 trial and ongoing real-world analyses mature, semaglutide-based regimens may be incorporated into asthma treatment guidelines as adjunct therapies for patients with metabolic comorbidities, fundamentally changing how we approach difficult-to-control obesity-related asthma.

7. Frequently Asked Questions

Can GLP-1 receptor agonists replace my asthma inhalers?

No. Current evidence positions GLP-1 RAs as potential adjunct therapy, not a replacement for established asthma treatments. Patients should continue prescribed inhaled corticosteroids and bronchodilators. GLP-1 RAs may reduce the frequency of exacerbations and the need for rescue oral corticosteroids, but are not yet approved as primary asthma therapies.

Should my endocrinologist know I have asthma before prescribing a GLP-1 RA?

Yes. Pulmonologists should assess the metabolic history of their asthma patients, and endocrinologists should obtain a complete respiratory history before prescribing GLP-1 RAs. Agent selection matters — patients with asthma may benefit from semaglutide over tirzepatide based on current evidence.

Do you need to be obese to benefit from GLP-1 RAs for asthma?

Early studies suggest a positive signal in both obese and non-obese asthma patients, highlighting the direct anti-inflammatory mechanism beyond weight loss. However, the strongest evidence to date is in patients with comorbid overweight or obesity.

Are GLP-1 RAs safe in asthma patients?

The most widely used GLP-1 RAs (particularly semaglutide) appear safe and potentially beneficial in patients with asthma. However, tirzepatide has been associated with increased asthma risk in some analyses, so clinical vigilance is warranted. As with any medication, decisions should be individualized based on the patient’s complete medical history.

References

1. Huang YC, Tsai MC, Lin TCC, et al. Glucagonlike peptide-1 receptor agonists and asthma risk in adolescents with obesity. JAMA Netw Open. 2025;8(12):e2551611. doi:10.1001/jamanetworkopen.2025.51611
2. Current Opinion in Pulmonary Medicine. GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads. PubMed 41664500. 2025.
3. Kulsum U, et al. Exploring the link between GLP-1 receptor agonists, type 2 diabetes, and asthma risk — Bayesian network meta-analysis. CHEST Conference. 2025.
4. GLP-1 receptor agonists in obesity-related asthma: exploring new treatment strategies. CHEST. 2025;S0012-3692(25)03954-6.
5. Breathtaking benefits? GLP-1 receptor agonists impact on asthma exacerbations. CHEST. 2025;S0012-3692(25)03987-X.
6. The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma. Exploration of Asthma and Allergy. January 2025.
7. Zhang M, Lin C, Cai X, et al. The association between GLP-1 receptor-based agonists and the incidence of asthma in patients with type 2 diabetes and/or obesity: a meta-analysis. Biomed Environ Sci. 2024.
8. Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base. Pharmaceutics. 2025;17(8):1036.
9. Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141:1169–1179.
10. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025. https://ginasthma.org/2025-gina-strategy-report/